• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Dante Labs Announces Appointment of Healthcare Veteran and GRAIL SVP Mark Morgan to Board Of Directors to Support Genomic and Precision Medicine Scaling in the United States

    8/9/21 7:39:23 AM ET
    $AMGN
    $ANTM
    $ILMN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Medical Specialities
    Health Care
    Get the next $AMGN alert in real time by email

    CAMBRIDGE, United Kingdom, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Dante Labs, a global leader in genomics and precision medicine, announced today the appointment of Mark Morgan as a board member. Mark is the SVP of Market Access for GRAIL, which has developed a highly innovative multi-cancer, early detection blood test.

    "We are excited to welcome Mark Morgan to the Dante Labs Board," said Dante Labs CEO Andrea Riposati, "Mark is a rockstar in healthcare. His deep experience with health plans, coupled with market access expertise in both biopharma and diagnostics will be invaluable to Dante Labs as we continue to build on our global success and expansion in the United States."

    Mr. Morgan stated, "The opportunity to work with Dante Labs to accelerate adoption of whole genome sequencing in the US for patients with rare diseases, oncology, cardiovascular and other conditions is incredibly exciting."

    Mr. Morgan has deep experience with payors in the US market as well as market access in both the diagnostic and pharmaceutical spaces. His work at GRAIL and Amgen also focused heavily on the oncology space. He also serves as a board member for several additional healthcare focused organizations. Prior to GRAIL, Mr. Morgan held senior leadership roles in consumer markets and network management at Blue Shield of California. Prior to that, Mr. Morgan held leadership roles at Amgen (NASDAQ:AMGN), including Market Access and Value Based Partnerships. Mr. Morgan also served at the President of Anthem (NYSE:ANTM) in California, and held various additional leadership roles with the healthcare space in his nearly 30-year career. Mr. Morgan will join Illumina (NASDAQ:ILMN) Chief Operations Officer Bob Ragusa to Dante Labs Board of Directors.

    About Dante Labs

    Dante Labs is a global genomic data company building and commercializing a new class of transformative health and longevity applications based on whole genome sequencing and AI. Our assets include one of the largest private genome databases with research consent, a proprietary software platform designed to unleash the power of genomic data at scale and proprietary processes which enable an industrial approach to genomic sequencing.

    Headquartered in Cambridge, United Kingdom, with a research laboratory in Wolverhampton, Dante Labs supported the UK Government's urgent requirement to scale-up a high-capacity, highly automated testing solution for Covid-19, including infected patients as well as those with antibodies. Dante Labs was able to deliver by leveraging existing technology that had been developed for whole genome sequencing.

    Contacts

    Giorgio Lodi

    [email protected]

    +39 0862 191 0671

    www.dantelabs.com 

    A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/93250a1b-93cb-40ac-80f2-b4981dfe61bc



    Primary Logo

    Get the next $AMGN alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $AMGN
    $ANTM
    $ILMN

    CompanyDatePrice TargetRatingAnalyst
    Amgen Inc.
    $AMGN
    5/20/2025$288.00Neutral
    Guggenheim
    Amgen Inc.
    $AMGN
    4/22/2025$305.00Neutral
    Cantor Fitzgerald
    Illumina Inc.
    $ILMN
    3/4/2025$130.00 → $90.00Neutral
    Citigroup
    Illumina Inc.
    $ILMN
    2/28/2025$100.00Buy → Hold
    HSBC Securities
    Illumina Inc.
    $ILMN
    2/10/2025$130.00 → $100.00Equal Weight → Underweight
    Barclays
    Illumina Inc.
    $ILMN
    2/7/2025$177.00 → $140.00Buy → Hold
    TD Cowen
    Illumina Inc.
    $ILMN
    12/11/2024$190.00 → $165.00Buy → Neutral
    Citigroup
    Amgen Inc.
    $AMGN
    12/10/2024$256.00Underperform
    BofA Securities
    More analyst ratings

    $AMGN
    $ANTM
    $ILMN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SVP, Chief Financial Officer Dhingra Ankur bought $495,381 worth of shares (6,100 units at $81.21), increasing direct ownership by 32% to 24,906 units (SEC Form 4)

      4 - ILLUMINA, INC. (0001110803) (Issuer)

      5/14/25 4:20:13 PM ET
      $ILMN
      Medical Specialities
      Health Care
    • Chief Executive Officer Thaysen Jacob bought $998,674 worth of shares (12,350 units at $80.86), increasing direct ownership by 17% to 83,390 units (SEC Form 4)

      4 - ILLUMINA, INC. (0001110803) (Issuer)

      5/14/25 4:18:28 PM ET
      $ILMN
      Medical Specialities
      Health Care
    • Thaysen Jacob bought $991,672 worth of shares (7,330 units at $135.29), increasing direct ownership by 97% to 14,861 units (SEC Form 4)

      4 - ILLUMINA, INC. (0001110803) (Issuer)

      2/26/24 8:57:29 AM ET
      $ILMN
      Medical Specialities
      Health Care

    $AMGN
    $ANTM
    $ILMN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • iRhythm Technologies Announces Board Member Retirements and New Director Appointments

      SAN FRANCISCO, July 07, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC) , a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today announced the retirement of two long-serving board members, Mark Rubash and Ralph Snyderman, M.D., effective July 7, 2025. Concurrently, Karen McGinnis and Kevin O'Boyle have accepted appointments to the board of directors. Mark Rubash has served on the board since 2016, prior to the company's initial public offering, bringing decades of experience in finance, accounting, and strategy at high-growth technology companies. Ralph Snyderman, M.D., who joined the board in 2017, br

      7/7/25 8:30:00 AM ET
      $ABSI
      $ATEC
      $ILMN
      $IRTC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
      Medical/Dental Instruments
      Medical Specialities
    • AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR BEMARITUZUMAB IN FIBROBLAST GROWTH FACTOR RECEPTOR 2b (FGFR2b) POSITIVE FIRST-LINE GASTRIC CANCER

      At an Interim Analysis, Bemarituzumab Plus Chemotherapy Significantly Improved Overall Survival in People With FGFR2b Overexpression Compared to Chemotherapy Alone THOUSAND OAKS, Calif., June 30, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the Phase 3 FORTITUDE-101 clinical trial evaluating first-line bemarituzumab plus chemotherapy (mFOLFOX6) met its primary endpoint of overall survival (OS) at a pre-specified interim analysis.  Bemarituzumab plus chemotherapy demonstrated a statistically significant and clinically meaningful improvement in OS as compared to placebo plus chemotherapy in people living with unresectable locally advanced or metastatic gastric or gastroesophageal j

      6/30/25 9:00:00 AM ET
      $AMGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Illumina to acquire SomaLogic, accelerating its proteomics business and advancing the company's multiomics strategy

      Combines highly complementary proteomics expertise with Illumina's industry-leading product innovation and global market reach Positions Illumina to achieve growth in a large, expanding market Illumina and SomaLogic have partnered in proteomics co-development since late 2021 SAN DIEGO, June 23, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) announced today it has entered into a definitive agreement with Standard BioTools (NASDAQ:LAB) under which Illumina will acquire SomaLogic, a leader in data-driven proteomics technology, and other specified assets for $350 million in cash payable at closing, subject to customary adjustments, plus up to $75 million in near-term performance-based milesto

      6/23/25 7:13:00 AM ET
      $ILMN
      $LAB
      Medical Specialities
      Health Care
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $AMGN
    $ANTM
    $ILMN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Ullem Scott B. was granted 307 shares, increasing direct ownership by 4% to 8,137 units (SEC Form 4)

      4 - ILLUMINA, INC. (0001110803) (Issuer)

      7/2/25 4:26:43 PM ET
      $ILMN
      Medical Specialities
      Health Care
    • SVP, Business Development Khosla Rachna sold $434,520 worth of shares (1,500 units at $289.68), decreasing direct ownership by 16% to 8,162 units (SEC Form 4)

      4 - AMGEN INC (0000318154) (Issuer)

      6/6/25 7:49:22 PM ET
      $AMGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Miles Amy E was granted 809 shares, increasing direct ownership by 20% to 4,842 units (SEC Form 4)

      4 - AMGEN INC (0000318154) (Issuer)

      5/28/25 9:07:13 PM ET
      $AMGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AMGN
    $ANTM
    $ILMN
    SEC Filings

    See more
    • SEC Form 8-K filed by Illumina Inc.

      8-K - ILLUMINA, INC. (0001110803) (Filer)

      6/23/25 9:24:49 AM ET
      $ILMN
      Medical Specialities
      Health Care
    • SEC Form 11-K filed by Amgen Inc.

      11-K - AMGEN INC (0000318154) (Filer)

      6/12/25 4:46:22 PM ET
      $AMGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 11-K filed by Amgen Inc.

      11-K - AMGEN INC (0000318154) (Filer)

      6/12/25 4:42:09 PM ET
      $AMGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AMGN
    $ANTM
    $ILMN
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for REPATHA issued to AMGEN INC

      Submission status for AMGEN INC's drug REPATHA (SUPPL-44) with active ingredient EVOLOCUMAB has changed to 'Approval' on 11/20/2024. Application Category: BLA, Application Number: 125522, Application Classification:

      11/21/24 12:43:07 PM ET
      $AMGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • FDA Approval for PAVBLU issued to AMGEN INC

      Submission status for AMGEN INC's drug PAVBLU (ORIG-1) with active ingredient AFLIBERCEPT has changed to 'Approval' on 08/23/2024. Application Category: BLA, Application Number: 761298, Application Classification:

      8/26/24 5:53:38 AM ET
      $AMGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • FDA Approval for REPATHA issued to AMGEN INC

      Submission status for AMGEN INC's drug REPATHA (SUPPL-43) with active ingredient EVOLOCUMAB has changed to 'Approval' on 08/20/2024. Application Category: BLA, Application Number: 125522, Application Classification:

      8/21/24 12:12:47 PM ET
      $AMGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AMGN
    $ANTM
    $ILMN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Guggenheim resumed coverage on Amgen with a new price target

      Guggenheim resumed coverage of Amgen with a rating of Neutral and set a new price target of $288.00

      5/20/25 8:11:08 AM ET
      $AMGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cantor Fitzgerald resumed coverage on Amgen with a new price target

      Cantor Fitzgerald resumed coverage of Amgen with a rating of Neutral and set a new price target of $305.00

      4/22/25 7:29:10 AM ET
      $AMGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Citigroup reiterated coverage on Illumina with a new price target

      Citigroup reiterated coverage of Illumina with a rating of Neutral and set a new price target of $90.00 from $130.00 previously

      3/4/25 8:10:42 AM ET
      $ILMN
      Medical Specialities
      Health Care

    $AMGN
    $ANTM
    $ILMN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Illumina Inc.

      SC 13G/A - ILLUMINA, INC. (0001110803) (Subject)

      12/6/24 10:11:24 AM ET
      $ILMN
      Medical Specialities
      Health Care
    • SEC Form SC 13G filed by Illumina Inc.

      SC 13G - ILLUMINA, INC. (0001110803) (Subject)

      12/5/24 7:27:01 PM ET
      $ILMN
      Medical Specialities
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Illumina Inc.

      SC 13G/A - ILLUMINA, INC. (0001110803) (Subject)

      11/12/24 3:59:44 PM ET
      $ILMN
      Medical Specialities
      Health Care

    $AMGN
    $ANTM
    $ILMN
    Leadership Updates

    Live Leadership Updates

    See more
    • Illumina Board of Directors elects Dr. Scott Gottlieb Chair, Keith Meister to join Board of Directors

      Stephen MacMillan to retire from the Board SAN DIEGO, March 25, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN), a global leader in DNA sequencing and array-based technologies, today announced changes to its Board of Directors. Scott Gottlieb, MD, has been elected non-executive Chair of Illumina's Board. Dr. Gottlieb has served on the Board of Directors since 2020. Additionally, Keith Meister, founder, Managing Partner, and Chief Investment Officer of Corvex Management, will join the Board of Directors on March 28, 2025. Stephen MacMillan, Chairman, President, and CEO of Hologic, who joined the Illumina Board in June 2023, has decided to retire from the board in preparation for the company

      3/25/25 9:00:00 AM ET
      $ILMN
      Medical Specialities
      Health Care
    • GeminiBio Appoints Mike Stella to Board

      Strengthening Board with Industry Veterans Gemini Bioproducts, LLC ("GeminiBio"), a biopharma and advanced therapy raw materials supplier, and a portfolio company of BelHealth Investment Partners, LLC ("BelHealth"), a Fort Lauderdale-based healthcare private equity firm, announced today the appointment of Michael Stella to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250218608576/en/Mike Stella, CEO of Ascend Advanced Therapies, joins the Board at GeminiBio to provide strategic leadership in the fields of cell and gene therapy contract development and manufacturing. (Photo: Business Wire) GeminiBio prov

      2/18/25 9:00:00 AM ET
      $AMGN
      $GSK
      $JNJ
      $MRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Industrial Machinery/Components
    • KKR, CrowdStrike Holdings and GoDaddy Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

      NEW YORK, June 7, 2024 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, June 24, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from the S

      6/7/24 6:09:00 PM ET
      $ADTN
      $ALTR
      $ATNI
      $BMRN
      Telecommunications Equipment
      Utilities
      Computer Software: Prepackaged Software
      Technology

    $AMGN
    $ANTM
    $ILMN
    Financials

    Live finance-specific insights

    See more
    • AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR BEMARITUZUMAB IN FIBROBLAST GROWTH FACTOR RECEPTOR 2b (FGFR2b) POSITIVE FIRST-LINE GASTRIC CANCER

      At an Interim Analysis, Bemarituzumab Plus Chemotherapy Significantly Improved Overall Survival in People With FGFR2b Overexpression Compared to Chemotherapy Alone THOUSAND OAKS, Calif., June 30, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the Phase 3 FORTITUDE-101 clinical trial evaluating first-line bemarituzumab plus chemotherapy (mFOLFOX6) met its primary endpoint of overall survival (OS) at a pre-specified interim analysis.  Bemarituzumab plus chemotherapy demonstrated a statistically significant and clinically meaningful improvement in OS as compared to placebo plus chemotherapy in people living with unresectable locally advanced or metastatic gastric or gastroesophageal j

      6/30/25 9:00:00 AM ET
      $AMGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Infinity Bio Closes $8M Series A Financing Led by Illumina Ventures to Expand Leadership in Antibody Reactome Profiling

      Investment supports platform innovation, commercial scaling, and new service development; Infinity acquires the assets of Serimmune, Inc. Infinity Bio, a biotechnology company pioneering technologies to map immune responses at scale, today announced the successful closing of an $8 million Series A financing round. The round was led by Illumina Ventures, with participation from PTX Capital, Blackbird BioVentures, and Propel Baltimore Fund. As part of the strategic plan to broaden its suite of service offerings, Infinity Bio has acquired the assets of Serimmune, Inc., which was founded in 2014 to provide unbiased antibody reactome services. New MIPSA™ service offerings, including EnviroSI

      6/18/25 9:00:00 AM ET
      $ILMN
      Medical Specialities
      Health Care
    • AMGEN'S PHASE 2 MARITIDE DATA TO BE PRESENTED AT THE AMERICAN DIABETES ASSOCIATION 85TH SCIENTIFIC SESSIONS

      MariTide is the First Monthly or Less Frequently Dosed Peptide-Antibody Conjugate Being Investigated for the Treatment of Obesity and Type 2 Diabetes  New Repatha® Data Provide Insight Into the Benefits of Lipid Lowering Therapy in People With Type 1 Diabetes Amgen to Host Investor Webcast on MariTide Data on June 23 at 4:30 p.m. CDT  THOUSAND OAKS, Calif., June 18, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced full results from Part 1 of the Phase 2 study for MariTide (maridebart cafraglutide, formerly AMG 133) in patients living with obesity, with and without Type 2 diabetes, will be presented along with new data from the Phase 3 FOURIER study of Repatha® (evolocumab) in cardio

      6/18/25 9:00:00 AM ET
      $AMGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care